Plain-English translation of NCT05010031 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether people with metastatic cancer and an ATM genetic mutation can be treated with lower doses of radiation therapy than are typically used. Researchers believe that because of this genetic change, these tumors may respond well to reduced radiation doses. The goal is to find the lowest effective dose that controls the cancer while minimizing side effects.
People with an ATM mutation may be more sensitive to standard radiation doses, which can cause serious complications. This study aims to find out if lower doses of the treatment can still work effectively, reducing harm while maintaining cancer control.
You likely qualify if…
You likely don't qualify if…
You would receive reduced-dose radiation treatment targeted at your metastatic lesions. The study uses a two-stage design, meaning researchers will check results after treating an initial group of patients to decide whether to continue. The research team will monitor whether the lower radiation doses control your cancer effectively and track how well you tolerate the treatment.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States